| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/05/2009 | CA2694510A1 Treatment with .alpha.7-selective ligands |
| 02/05/2009 | CA2694504A1 (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof |
| 02/05/2009 | CA2694485A1 Endoparasiticidal topical compositions |
| 02/05/2009 | CA2694462A1 Thiophosphi(o)nic acid derivatives and their therapeutical applications |
| 02/05/2009 | CA2694389A1 Treatment of pediatric tumors |
| 02/05/2009 | CA2694378A1 Pharmaceutical compositions and process for making them |
| 02/05/2009 | CA2694362A1 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands |
| 02/05/2009 | CA2694359A1 Novel heterocyclic compounds as mglu5 antagonists |
| 02/05/2009 | CA2694325A1 Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same |
| 02/05/2009 | CA2694276A1 Monoamide derivatives as orexin receptor antagonists |
| 02/05/2009 | CA2694218A1 Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment |
| 02/05/2009 | CA2694136A1 Pi3 kinase modulators and methods of use |
| 02/05/2009 | CA2694108A1 Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type i and ii diabetes mellitus |
| 02/05/2009 | CA2694098A1 Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type i and ii diabetes mellitus |
| 02/05/2009 | CA2693820A1 2-aza-bicyclo[3.3.0]octane derivatives |
| 02/05/2009 | CA2693817A1 Trans-3-aza-bicyclo[3.1.0]hexane derivatives |
| 02/05/2009 | CA2693715A1 Pyrrolopyrimidines |
| 02/05/2009 | CA2693551A1 Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use |
| 02/05/2009 | CA2693390A1 Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same |
| 02/05/2009 | CA2693364A1 A medicament for treating glaucoma comprising as an active ingredient cyclodextrin-clathrate compound of cilostazol |
| 02/05/2009 | CA2693340A1 Pyrone analog compositions and methods |
| 02/05/2009 | CA2693338A1 Phosphorylated pyrone analogs and methods |
| 02/05/2009 | CA2693266A1 Novel synthetic agonists of tlr9 |
| 02/05/2009 | CA2692071A1 Fly control method |
| 02/05/2009 | CA2691866A1 6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof |
| 02/05/2009 | CA2691781A1 Flea control method |
| 02/05/2009 | CA2691779A1 Fly control method |
| 02/05/2009 | CA2691778A1 Ectoparasite control method |
| 02/05/2009 | CA2685962A1 Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification |
| 02/05/2009 | CA2683807A1 Novel combinations of neramexane for the treatment of neurodegenerative disorders |
| 02/05/2009 | CA2681021A1 Single-phase pharmaceutical composite preparation (dienogest and ethinyl estradiol) for oral therapy for regulation of blood pressure |
| 02/05/2009 | CA2677049A1 Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer |
| 02/04/2009 | EP2020416A1 Phosphonocephem compound |
| 02/04/2009 | EP2020414A1 spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| 02/04/2009 | EP2020412A1 Sulphur containing amino pyrimidine compounds for the treatment of inflammatory disorders |
| 02/04/2009 | EP2020411A1 Spiro tetracyclic compound |
| 02/04/2009 | EP2020410A1 Pyrido[2,3d]pyrimidine derivatives, process for their preparation and their therapeutical use |
| 02/04/2009 | EP2020409A1 New piperidinyl derivatives as modulators of chemokine receptor activity |
| 02/04/2009 | EP2020408A1 Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 02/04/2009 | EP2020406A1 New antimicrobial compounds, their synthesis and their use for treatment of mammalian infection |
| 02/04/2009 | EP2020405A1 Substituted aryl or heteroarylpiperidine derivatives as melanocortin-4 receptor modulators |
| 02/04/2009 | EP2020404A1 Cyanomethyl substituted N-Acyl Tryptamines |
| 02/04/2009 | EP2020256A1 Sulfur containing dermatological compositions |
| 02/04/2009 | EP2020243A1 Topically applicable pharmaceutical preparation |
| 02/04/2009 | EP2020242A2 Improved Topical Medicaments and Methods for Photodynamic Treatment of Disease |
| 02/04/2009 | EP2020237A2 Ceramide and chemotherapeutic agents for inducing cell death |
| 02/04/2009 | EP2020236A1 Contraceptive medicament based on a progestative and oestrogen, method for producing the same, and use |
| 02/04/2009 | EP2020235A1 Method for manufacturing a single-phase pharmaceutical preparation for oral treatment to regulate blood pressure |
| 02/04/2009 | EP2020234A1 Synergic combination of l-type calcium-channel blockers with selective action in respect of the gastrointestinal tract and an inert silicone |
| 02/04/2009 | EP2020233A2 Use Of A Hydroximic Acid Halide Derivative In The Treatment Of Neurodegenerative Diseases |
| 02/04/2009 | EP2020232A1 N-(1-thiazolyl)-amide derivatives for the treatment of obesity, diabetes and cardiovascular diseases |
| 02/04/2009 | EP2020231A1 Fat absorption inhibitor |
| 02/04/2009 | EP2020230A1 Combination of at least two 5-HT6-Ligands |
| 02/04/2009 | EP2020229A1 Multiparticulate modified release composition |
| 02/04/2009 | EP2020228A2 Skin cosmetic composition |
| 02/04/2009 | EP2019952A2 Stabilized formulation of triamcinolone acetonide |
| 02/04/2009 | EP2019835A1 Oligonucleotides affecting expression of phosphodiesterases |
| 02/04/2009 | EP2019834A1 Ectonucleotidase inhibitors |
| 02/04/2009 | EP2019831A1 Nicotinic acetylcholine receptor ligands 101 |
| 02/04/2009 | EP2019830A2 Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus |
| 02/04/2009 | EP2019829A1 N- ( 2-thiazolyl) -amide derivatives as gsk-3 inhibitors |
| 02/04/2009 | EP2019828A1 N- (2-thiazolyl) -amide derivatives as gsk-3 inhibitors |
| 02/04/2009 | EP2019827A1 Integrase inhibitors 3 |
| 02/04/2009 | EP2019826A1 Thiophene-carboxamides useful as inhibitors of protein kinases |
| 02/04/2009 | EP2019825A1 Inhibitors of human immunodeficiency virus replication |
| 02/04/2009 | EP2019824A2 Benzamide glucokinase activators |
| 02/04/2009 | EP2019823A2 Benzamide glucokinase activators |
| 02/04/2009 | EP2019820A1 Therapeutic pyrrolidine compounds |
| 02/04/2009 | EP2019720A2 Treating muscular disorders and improving muscular function |
| 02/04/2009 | EP2019693A2 High molecular weight chelation structure |
| 02/04/2009 | EP2019692A2 Compounds and methods for modulating expression of gccr |
| 02/04/2009 | EP2019680A1 Augmentation of titer for vaccination in animals |
| 02/04/2009 | EP2019679A2 Glucose transport inhibitors and methods of use |
| 02/04/2009 | EP2019678A2 Novel silicone film former for delivery of actives |
| 02/04/2009 | EP2019677A2 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 02/04/2009 | EP2019676A2 Method for increasing the bioavailability of benzhydryl piperazine containing compounds |
| 02/04/2009 | EP2019675A1 Methods for treating or preventing neoplasias |
| 02/04/2009 | EP2019674A2 Histone deacetylase and tubulin deacetylase inhibitors |
| 02/04/2009 | EP2019673A2 Compounds for the treatment of metabolic disorders |
| 02/04/2009 | EP2019672A2 Unit dose formulations comprising an inhalable solution of albuterol |
| 02/04/2009 | EP2019671A2 Bivalent smac mimetics and the uses thereof |
| 02/04/2009 | EP2019666A2 Pharmaceutical preparations for transdermal use |
| 02/04/2009 | EP2019664A1 Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same |
| 02/04/2009 | EP2019663A2 Compositions comprising at least one naphthoic acid derivative and benzoyl peroxide, methods for preparing same, and uses thereof |
| 02/04/2009 | EP2019593A1 Pro-drugs of tertiary alcohols |
| 02/04/2009 | EP2019592A1 5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin and its preparation and use for the treatment of cancer |
| 02/04/2009 | EP2019586A2 Acute pain medications based on fast acting diclofenac-opioid combinations |
| 02/04/2009 | EP2019585A2 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| 02/04/2009 | EP1824817B1 Arylsulfonylnaphthalene derivatives as 5ht2a antagonists |
| 02/04/2009 | EP1733161A4 Device and method for pneumatic valve control |
| 02/04/2009 | EP1660509B1 Glucopyranosyloxy- pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof |
| 02/04/2009 | EP1660097B1 Physiologically active composition based on phosphatidylserine |
| 02/04/2009 | EP1596842B1 Dermal, transdermal, mucosal or transmucosal ingredient delivery devices |
| 02/04/2009 | EP1587515A4 Biologic skin repair and enhancement |
| 02/04/2009 | EP1565422B1 Vitamin d receptor modulators |
| 02/04/2009 | EP1551818B1 Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands |
| 02/04/2009 | EP1542976B1 Substituted 4-(indazol-3-yl)phenols as estrogen receptor (er) ligands and their use in the treatment of inflammatory diseases |
| 02/04/2009 | EP1492773B1 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation |
| 02/04/2009 | EP1414410B1 Nanoparticulate formulations of fenofibrate |
| 02/04/2009 | EP1299529B1 Conserved diaphanous-related formin autoregulatory domain (dad) |